# Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

> **NCT05974410** · — · AVAILABLE · sponsor: **AVM Biotechnology Inc**

## Conditions studied

- Glioblastoma
- Squamous Cell Carcinoma
- Hodgkin Lymphoma
- Non-hodgkin Lymphoma
- Breast Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Acute Leukemia
- Pancreatic Cancer
- Spindle Cell Sarcoma
- Cancer
- Tumor, Solid
- Tumor, Brain
- Esophageal Andeocarcinoma
- Mixed Phenotype AML
- Desmoplastic Round Cell Sarcoma

## Interventions

- **DRUG:** AVM0703
- **DRUG:** Hydrocortisone
- **DRUG:** Proton pump inhibitor

## Key facts

- **NCT ID:** NCT05974410
- **Lead sponsor:** AVM Biotechnology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05974410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05974410, "Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05974410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*